NIO Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? NIO Inc. trades at $4.56 (market cap $12.12B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 6.9× NIO Inc.'s market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while NIO Inc. pays none. Which is the better fit depends on your goals.
| NIO | REGN | |
|---|---|---|
Market Cap | $12.12B | $83.19B |
Sector | Consumer Cyclical | Health |
52-Week High | $7.89 | $812.27 |
52-Week Low | $4.44 | $555.51 |
Enterprise Value | $11.35B | $77.90B |
Dividend Yield | — | 0.47% |
Signals from Pluang's Aura AI — not financial advice
NIO trades at $4.74, up 3.04% today but remains under pressure with a bearish technical signal. The company shows strong revenue growth to $87.49 billion in 2025, but profitability remains elusive with a net loss of $15.57 billion. Analyst sentiment is mixed with a 54% buy rating, while recent news highlights delivery growth amid a challenging EV market.
NIO's outlook hinges on achieving profitability amid fierce competition. The stock offers potential for recovery if cost controls improve and deliveries accelerate, but risks include persistent losses, high debt, and macroeconomic pressures in China. Investor patience is required given the long path to sustained earnings.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Trailing returns across standard periods
Latest headlines on both assets
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →